BackNymox Pharmaceutical Overview

Nymox Pharmaceutical Other Current Assets

Nymox Pharmaceutical's other current assets is $44K.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$44000.00
38.89% YoYΔ $-28000.00 vs prior year quarter

Peer average / median

Loading

Nymox Pharmaceutical Other Current Assets History

Loading

Nymox Pharmaceutical vs. peers: Other Current Assets Comparison

Loading

Nymox Pharmaceutical Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Nymox Pharmaceutical (NYMX) FAQ

The latest other current assets for NYMX is $44K as of June 2023. That compares with $72K in the prior-year period — down 38.9% year over year. Investors often review this figure alongside Nymox Pharmaceutical's historical trend and sector peers before judging valuation or financial health.

Over the past year, NYMX's other current assets moved from $72K to $44K — a 38.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nymox Pharmaceutical's operating scale or balance-sheet position.

A other current assets figure of $44K for NYMX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NYMX's other current assets ($44K), review year-over-year change from $72K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Nymox Pharmaceutical's other current assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.